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Abstract
Background: In Germany, most breast cancer patients are treated in specialized breast cancer units (BCU), which
are certified, and routinely monitored. Herein, we evaluate up-to-date oncological outcome of breast cancer (BC)
molecular subtypes in routine clinical care of a specialized BCU.
Methods: The study was a prospectively single-center cohort study of 4102 female cases with primary, unilateral,
non-metastatic breast cancer treated between 01 January 2003 and 31 December 2012. The five routinely used
molecular subtypes (Luminal A-like, Luminal B/HER2 negative-like, Luminal B/HER2 positive-like, HER2-type, Triple
negative) were analyzed. The median follow-up time of the whole cohort was 55 months. We calculated estimates
for local control rate (LCR), disease-free survival (DFS), distant disease-free survival (DDFS), overall survival (OS),
and relative overall survival (ROS).
Results: Luminal A-like tumors were the most frequent (44.7 %) and showed the best outcome with LCR of 99.1 %
(95 % CI 98.5; 99.7), OS of 95.1 % (95 % CI 93.7; 96.5), and ROS of 100.0 % (95 % CI 98.5; 101.5). Triple negative
tumors (12.3 %) presented the poorest outcome with LCR of 89.6 % (95 % CI 85.8; 93.4), OS of 78.5 % (95 % CI 73.8;
83.3), and ROS of 80.1 % (95 % CI 73.8; 83.2).
Conclusions: Patients with a favorable subtype can expect an OS above 95 % and an LCR of almost 100 % over
5 years. On the other hand the outcome of patients with HER2 and Triple negative subtypes remains poor,
thus necessitating more intensified research and care.
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Background
Breast cancer (BC) mortality has declined over the past
decade in most developed countries, due to new
developments in screening, diagnostics, surgery, radio-
therapy, and (neo) adjuvant systemic therapy, in
conjunction with structural improvements (multidisci-
plinarity, implementation of specialized breast cancer
units) and target agreements (evidence-based guide-
lines, certification processes) [1, 2]. Over the past
decade, increasing molecular and genetic knowledge
[3–6] has provided a new understanding of breast can-
cer as a heterogeneous, systemic disease that can be
classified into different subtypes with different clinical
and pathological features, different therapeutic re-
sponse patterns, and different outcomes [7, 8]. The
main molecular classification of breast cancer have
been distinguished by gene expression profiling into in-
trinsic subtypes by Peru et at [5]. These modern
microarray-based gene expression profiles (GEP) are
the best way to visualize the heterogeneity of breast
cancer, but lacking gene expression profiling in clinical
* Correspondence: joerg.heil@med.uni-heidelberg.de
†Equal contributors
1Department of Gynecology and Obstetrics, University of Heidelberg, Im
Neuenheimer Feld 440, 69120 Heidelberg, Germany
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Hennigs et al. BMC Cancer  (2016) 16:734 
DOI 10.1186/s12885-016-2766-3
routine due to cost and practicability made a surrogate
classification necessary [9]. The molecular subtypes of
breast cancer correspond reasonably well to a clinical
characterization on the basis of hormone-and HER2
status, as well as proliferation markers or histological
grade [10]. So the classification based on immunohisto-
chemistry (IHC) markers was recommended by the St.
Gallen Expert Consensus in 2011 [11] and confirmed
again in 2013 [12]. It has become the accepted standard in
routine clinical patient care. Classification into five mo-
lecular subtypes (Luminal A-like, Luminal B/HER2
negative-like, Luminal B/HER2 positive-like, HER2-type,
Triple negative) helps to sort patients into groups with
divergent prognoses and different response patterns to
specific Every-day-routine outcome assessment of
specialized breast cancer unit (BCU) must validate
guideline-based care of BC patients in order to
optimize the therapy of every individual case. This
paper reports the outcome data of a prospective
cohort of 4102 patients with primary, unilateral,
non-metastatic BC treated at a specialized BCU
according to routinely used molecular subtype defi-
nitions based on immunohistochemistry markers.
Methods
Patients
Since 01 January 2003 the medical history and the
demographic, diagnostic, therapeutic, and follow-up data
of all breast cancer patients referred to the BCU at
Heidelberg University have been prospectively entered
into our database. This register is routinely used for
certification purposes and is monitored.
Patients from the registry were included in the present
analysis if they had invasive or carcinoma-in-situ cancer
of the breast and were newly diagnosed or treated
between 01 January 2003 and 31 December 2012.
Patients were excluded from this analysis for any of the
following reasons: male sex (n = 38), distant metastasis at
the intake visit (M1, n = 296) or bilateral tumors (n = 619).
Patients with incomplete immunohistological informa-
tion (149, i.e. 4.1 % of 3603) were included in the overall
analysis, but they could not be considered in the sub-
group outcome analysis.
Histology and stage
Tumors were defined according to the World Health
Organization [13], graded along Elston and Ellis [14], and
grouped into stages according to the TNM classification
[15]. The expression of estrogen receptor (ER), progester-
one receptor (PR), human epidermal growth factor receptor
2 (HER2), and Ki-67 were assessed with an IHC assay of
formalin-fixed, paraffin-embedded tumor tissue according
to international standards.
Subgroups
According to the St. Gallen International Expert Consensus
recommendations 2011 [11], five molecular subtypes of
invasive breast cancer have been differentiated by their
expression of the IHC markers ER, PR, HER2, and Ki-67:
The classification of 2011 was used because it corre-
sponded best to the way we had categorized patients
during the time period covered in this report [11].
Positivity for ER and PR was defined as an Immunoreac-
tive Score [16] of at least 1 out of 12 or a Total Score [17]
of at least 1 out of 8. All cases of non-invasive carcinoma-
in-situ (CIS, regardless of specific subtype) have been
defined as an additional subgroup for a separate analysis.
For invasive BC, the cell proliferation marker Ki-67
was available in the majority of our cohort (3004/3603,
83.4 %), while grading, either 1 or 3, was used in 599 of
the 3603 cases (16.6 %) for subgroup classification
(Table 1). For the differentiation of Luminal-like tumors,
cases with a negative HER2 receptor status in combin-
ation with a positive ER or PR receptor and a grading of
1 led to the attribution of the Luminal A-like subgroup.
In contrast a grading of G3 was assigned to the sub-
group of Luminal B/HER2 negative-like tumors.
Treatment
The Heidelberg University BCU was fully certified on 10
October 2003, by the German certification board of the
German Cancer Society and the German Society for
Senology on the basis of the management of cases in
2002 and 2003. Thus all the cases included in this study
were managed under certified conditions, which were
confirmed by an annual re-certification process [18, 19].
Endpoints and outcome assessment
The outcome from the time of diagnosis was assessed
for the whole cohort, the five BC subtypes, and the CIS
cases for several outcome parameters. The endpoints were
local control rate (LCR), disease-free survival (DFS),
distant disease-free survival (DDFS), overall survival (OS),
and relative overall survival (ROS). Relative survival was
Intrinsic suptype ER and/or PR HER2 Ki-67
Luminal A-like (LumA) + − <14 %
Luminal B/HER2
negative-like
(LumB/HER2 neg.) + − ≥14 %
Luminal B/HER2
positive-like
(LumB/HER2 pos.) + + any
HER2-type (HER2) both− + any
Triple negative (TN) both− − any
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Table 1 Patient, tumor, and surgical therapy characteristics of
all female cases with primary, non-metastatic, unilateral breast
cancer diagnosed at the Heidelberg Breast Care Unit between
01 January 2003 and 31 December 2012
Total cases (n = 4102) Number of cases Percent (%)
Patient characteristics
Age at diagnosis in years (n = 4102)
median 57 years
< 51 1355 33.0
51–65 1638 39.9
> 65 1109 27.0
total 4102 100.0
Menopausal status (n = 4102)
pre 1377 33.6
peri 130 3.2
post 2498 60.9
missing 97 2.4
total 4102 100.0
Affected breast (n = 4102)
left 2066 50.4
right 2036 49.6
total 4102 100.0
Tumor characteristics
Main tumor histology (n = 4102)
In-situ Carcinoma 499 12.2
Invasive Carcinoma 3603 87.8
Invasive ductal carcinoma
(no specific type)
3082 85.5
Invasive lobular carcinoma 481 13.3
other (e.g. invasive medullar/mixed) 40 1.1
total 4102 100.0
T stage for invasive cases with
adjuvant therapy (n = 2997)
pT1 1863 62.2
pT1a 161
pT1b 486
pT1c 1202
pTmic 7
unknown 7
pT2 909 30.3
pT3 138 4.6
pT4 58 1.9
pTx/missing 29 1.0
total 2997 100.0
T stage for invasive cases with
neoadjuvant therapy (n = 606)
ypT0 168 27.7
ypTis 16 2.6
Table 1 Patient, tumor, and surgical therapy characteristics of
all female cases with primary, non-metastatic, unilateral breast
cancer diagnosed at the Heidelberg Breast Care Unit between
01 January 2003 and 31 December 2012 (Continued)
ypT1 224 37.0
ypT1a 47
ypT1b 52
ypT1c 115
ypTmic 8
unknown 2
ypT2 127 21.0
ypT3 47 7.8
ypT4 16 2.6
ypTx/missing 8 1.3
total 606 100.0
N stage for invasive cases (n = 3603)
pN0 2473 68.6
pN1 655 18.2
pN2 243 6.7
pN3 158 4.4
pNx/missing 74 2.1
total 3603 100.0
Grading (invasive cases, n = 3603)
Grade 1 600 16.7
Grade 2 1924 53.4
Grade 3 962 26.7
missing 117 3.2
total 3603 100.0
Estrogen receptor
(invasive cases, n = 3603)
positive 2877 79.9
negative 585 16.2
missing 141 3.9
total 3603 100.0
Progesterone receptor
(invasive cases, n = 3603)
positive 2599 72.1
negative 859 23.8
missing 145 4.0
total 3603 100.0
HER2 receptor
(invasive cases, n = 3603)
positive 346 9.6
negative 3118 86.5
missing 139 3.9
total 3603 100.0
Ki-67 status
(invasive cases, n = 3603)
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defined as the ratio of the observed survival to the survival
expected in the general West German population of the
same age and sex during the same period of time [20].
Outcome was assessed as follows. First, hospital records
were reviewed to obtain information with regard to
survival, local and regional relapse, and distant metastasis.
If outcome information was not available in the hospital
record, the patient’s family doctor or gynecologist was
contacted by mail or phone. If the required information
could not be obtained by this approach either, an inquiry
about the patient’s survival status was made at the respon-
sible residents’ registration office. If the patient was still
alive, she was contacted by mail and asked whether she
had developed local or distant relapse with a detailed
questionnaire. Follow-up was performed for cases diag-
nosed until 31 December 2012. Within this study period
(starting 01 January 2003) n = 2322 patients had a
complete follow-up information (i.e. could be followed
until either death or study end. Of the remaining 1780
patients, 140 were lost to follow-up during the years
2003–2011, i.e. in total 140/4102 (3.4 %). The median time
of follow-up was 45 months among those who were lost
to follow-up, slightly shorter than among the whole cohort
(55 months).
Statistical analysis
The data were analyzed using SAS software version 9.3
(SAS Institute Inc.; Cary, NC, USA) and SPSS software
version 22 (IBM; Armonk, NY, USA). The proportions
of patients experiencing events at 5 years, the correspond-
ing 95 % confidence intervals (95 % CI), and all survival
plots are based on Kaplan-Meier estimates using PROC
LIFETEST with the actuarial approach. Relative survival
rates at 5 years were also calculated. The expected survival
of the general population was calculated according to the
Ederer II method [21], based on life tables for Germany
for the years 2002 to 2010.
Results
Patient characteristics
The final cohort comprised 4102 patients, of which, 3603
(87.8 %) had invasive carcinoma and 499 (12.2 %) had
CIS. Most invasive carcinoma cases were hormone recep-
tor positive (ER: 79.9 %, PR: 72.1 %), HER2 negative
(86.5 %), and had a grading of 2 (53.4 %). Most of the pa-
tients had a maximum tumor size of 2 cm (pT1: 62.2 %)
without axillary lymph node involvement (pN0 68.6 %).
Median age of the whole cohort was 57 years and most
patients were postmenopausal (60.9 %). Breast conserva-
tion surgery was performed in 73.1 % of the study cohort
and a mastectomy in 26.9 %. Concerning surgical manage-
ment of the axilla sentinel lymph node biopsy alone
(SLND) was performed in 40.7 % and axillary lymph node
dissection in 39.0 % of the patients. Detailed patient char-
acteristics of the cohort are shown in Table 1.
The UICC stage distribution (Additional file 1: Table S4)
as well as the frequency of age, menopausal status and
laterality (Additional file 2: Table S5) for the different
subtypes can be found in the supplementary material.
Outcome analysis
For all patients with invasive disease, LCR was 96.1 %
(95 % CI 95.3; 96.9); DFS was 83.7 % (95 % CI 82.2;
85.2); DDFS was 85.7 % (95 % CI 84.3; 87.1); OS was
90.5 % (95 % CI 89.3; 91.7) and ROS was 97.7 % (95 %
CI 93.4; 96.0) at 5 years. As regards cancer subtypes,
44.7 % were luminal A-like, 31.8 % Luminal B/HER2
negative-like, 6.2 % Luminal B/HER2 positive-like, 5.0 %
HER2-type, and 12.3 % Triple negative. The Luminal A-
like subtype showed the best outcome: LCR was 99.1 %
(95 % CI 98.5; 99.7); DFS was 92.1 (95 % CI 90.5; 93.9);
DDFS was 92.9 % (95 % CI 91.3; 94.5); OS was 95.1 %
(95 % CI 93.7; 96.5) and ROS was 100.0 % (95 % CI 98.5;
101.5). The Triple negative subtype had the worst out-
come: LCR at 5 years was 89.6 % (95 % CI 85.8; 93.4);
DFS was 69.1 % (95 % CI 64.1; 74.1); DDFS was 72.2 %
(95 % CI 67.3; 77.1); OS was 78.5 % (95 % CI 73.8; 83.2);
and ROS was 80.1 % (95 % CI 75.1; 85.1). Outcome mea-
sures for the whole cohort, with or without inclusion of
CIS cases, and for all clinico-pathological subtypes at
5 years are presented in Tables 2 and 3. The correspond-
ing Kaplan-Meier plots are shown in Figs. 1 and 2.
Table 1 Patient, tumor, and surgical therapy characteristics of
all female cases with primary, non-metastatic, unilateral breast
cancer diagnosed at the Heidelberg Breast Care Unit between
01 January 2003 and 31 December 2012 (Continued)
< 14 % 1463 40.6
≥ 14 % 1541 42.8
missing 599 16.6
total 3603 100.0
Surgical therapy characteristics
Surgical therapy (n = 4102)
Breast Conserving Surgery 2999 73.1
Mastectomy 1103 26.9
total 4102 100.0
Axillary staging (n = 4102)
SLND only 1671 40.7
SLND + ALND 501 12.2
ALND only 1600 39.0
none 330 8.1
total 4102 100.0
SLND sentinel lymphadenectomy, ALND axillary lymphadenectomy
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Additional outcome analyses for subtypes subdivided
into UICC stages I-IIa (Additional file 3: Table S6) can
be found in the supplementary material.
Discussion
The 5-year OS for all patients with primary invasive breast
cancer was 90.5 % (95 % CI 89.3; 91.7), and the ROS was
94.7 % (95 % CI 93.4; 96.0) (Table 2). This confirms the fa-
vorable prognosis of primary non-metastatic breast cancer
receiving adequate treatment. In this study, we focused on
a well-defined and homogenous patient cohort. The out-
comes seen here can be expected at any specialized BCU.
Most of the outcomes statistics published in the literature
derive from clinical trials with the exclusion of certain types
of patients commonly seen in routine care, e.g. the elderly
patients with comorbid conditions. Thus, it is important to
assess outcomes among a complete, unselected patient
population seen in a routine clinical setting. On the basis of
the favorable outcome results reported here, additional
quality-of-life aspects might be brought more into focus for
outcome quality for specific subgroups in the future.
In the face of unavailable gene expression profiles in
clinical routine, the BC surrogate classification according
to the St. Gallen Consensus 2011 [11] allows a differenti-
ation of five molecular subtypes with distinct prognoses.
Although the management of BC patients according to
these subtypes has gained importance, it is beyond contro-
versy that the traditionally assessed tumor characteristics,
e.g. nodal status and tumor size, still have independent
prognostic impact [22]. Because the St. Gallen subtype
classification is widely accepted as a surrogate for subtyp-
ing according to intrinsic signatures [9], we used this
classification for subtype-specific outcome analysis as they
are distinct and well applicable in the context of outcome
assessment. Standard pathological assessments seem
adequate to define useful groups such as TN, HER2-type,
and LumB/HER2 pos.-like tumors, for which treatment
recommendations are seldom controversial [23]. In
contrast to other studies (e.g. [24]), the Ki-67 score was
available for the vast majority of cases, enabling us to
differentiate the Luminal-like HER2 negative tumors.
Nevertheless, the validity and robustness of Ki-67 is still
controversial, although it has been widely accepted as a
cell proliferation marker that is widely available [25].
Especially the St. Gallen 2011 cut-off recommendation of
14 % for Ki-67 (which was proposed and validated by
Table 2 Five-year outcomes of 5 different endpoints for all female patients with primary, non-metastatic, unilateral breast cancer
treated at the Heidelberg Breast Care Unit between 01 January 2003 and 31 December 2012
All patients (including in-situ)
n = 4102 (including 499 in-situ cases)
Patients with invasive cancer
(excluding in-situ) n = 3603
LCR [%] (95 % CI) 96.1 (95.3; 96.9) 96.1 (95.3; 96.9)
DFS [%] (95 % CI) 84.9 (83.6; 86.2) 83.7 (82.2; 85.2)
DDFS [%] (95 % CI) 86.9 (85.7; 88.1) 85.7 (84.3; 87.1)
OS [%] (95 % CI) 91.3 (90.2; 92.4) 90.5 (89.3; 91.7)
ROS [%] (95 % CI) 95.5 (94.3; 96.7) 94.7 (93.4; 96.0)
CI confidence interval, LCR local recurrence rate, DFS disease-free survival, DDFS distant disease-free survival, OS observed overall survival, ROS relative
overall survival
Table 3 Outcome results of 5 different endpoints for all female cases with primary, non-metastatic, unilateral breast cancer treated at
the Heidelberg Breast Care Unit between 01 January 2003 and 31 December 2012, (for whom all necessary histological information were
available for distinct subtype attribution), differentiated by the invasive clinico-pathological tumor subtype or in-situ tumor (CIS). Results
in percent at 5 years (95 % CI)
INVASIVE CANCER CIS
LumA-like LumB/HER2
neg.-like
LumB/HER2
pos.-like
HER2-type Triple
negative
n = 3454 (100 %)
[missing due failed distinct subtype distribution n = 149, i.e. 4.1 % of invasive cohort]
n = 499
(100 %)
n = 1545 n = 1099 n = 215 n = 171 n = 424
44.7 % 31.8 % 6.2 % 5.0 % 12.3 %
LCR [%] (95 % CI) 99.1 (98.5; 99.7) 95.2 (93.6; 96.8) 95.0 (91.3; 98.7) 90.5 (84.7; 96.3) 89.6 (85.8; 93.4) 96.2 (93.9; 98.5)
DFS [%] (95 % CI) 92.2 (90.5; 93.9) 80.1 (77.2; 83.0) 79.0 (71.9; 86.1) 77.0 (69.4; 84.6) 69.1 (64.1; 74.1) 93.0 (90.2; 95.8)
DDFS [%] (95 % CI) 92.9 (91.3; 94.5) 82.2 (79.5; 84.9) 82.8 (76.0; 89.6) 83.3 (76.6; 90.0) 72.2 (67.3; 77.1) 95.6 (93.5; 97.1)
OS [%] (95 % CI) 95.1 (93.7; 96.5) 88.7 (86.2; 91.2) 92.5 (87.9; 97.1) 85.6 (78.6; 92.6) 78.5 (73.8; 83.2) 96.9 (94.8; 99.0)
ROS [%] (95 % CI) 100.0 (98.5; 101.5) 93.4 (90.7; 96.1) 96.0 (91.2; 100.8) 88.8 (81.5; 96.1) 80.1 (75.1; 85.1) 100.8 (98.6; 103.0)
CI confidence interval, LCR local recurrence rate, DFS disease-free survival, DDFS distant disease-free survival, OS observed overall survival, ROS relative overall
survival, CIS carcinoma-in-situ
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Cheang et al. [26]) has been viewed critically due to a
substantial inter-observer and intra-observer variability,
especially for mid-range Ki-67 scores [27–29]. This
discordance is highly problematic because a recommenda-
tion for or against chemotherapy for hormone receptor
positive, HER2 negative, grade 2 tumors depends mainly
on the Ki-67 threshold in the St. Gallen Consensus 2011.
Because of this ambiguity in defining exact surrogate
subtypes it might be difficult to compare subtype
outcome results with other studies that used different
surrogate definitions. Despite this difficulty in compari-
son with other study designs the general trend concern-
ing distribution (at least for clear defined subtypes like
TN) and outcome in our cohort is in approximate ac-
cordance with other results e.g. from Canada [30], USA
[31, 32], South Korea [33], Belgium [24], Spain [34, 35],
Italy [36] and France [37]: LumA and LumB tumors
were the most frequent (LumA was 44.7 %, LumB/HER2
neg. was 31.8 %, and LumB/HER2 pos. was 6.2 %),
followed by TN cancers (12.3 %) and HER2 type (5.0 %).
For the majority of patients with a Luminal A type a very
favorable OS over 5 years of 95.1 % (95 % CI 93.7; 95.5)
and an excellent LCR of 99.1 % (95 % CI 98.5; 99.7) was
possible. But it becomes also evident that outcome
possibilities for HER-2 type and TN cases are still much
poorer even in times of more effective systemic treat-
ment (Table 3). Two exemplary studies with large
cohorts-the single-hospital report from Broukhaert et al.
in Belgium [24] and the population-based report from
Minicozzi et al. in Italy [36]-both used similar criteria
approximating the St. Gallen 2011 classification. These
two studies had quite comparable distributions of BC
subtypes (42 % and 56 % for LumA-like, 27 % and 22 %
for LumB/HER2 neg.-like, 14 % and 7 % for LumB/
HER2 pos.-like, 7 % and 4 % for HER2-type, and 11 %
and 10 % for TN). And these two studies also found simi-
lar outcomes; the DFS over 5 years was 93.0 % and 94.6 %
for LumA-like, 87.4 % and 85.7 % for Lum B/HER2 neg.-
like, 86.3 % and 86.8 % for LumB/HER2 pos.-like, 77.9 %
and 79.7 % for HER2-type, and 80.5 % and 81.0 % for TN.
DFS was somewhat lower for LumB-like and TN in our
cohort than in those two other studies. Besides slightly
different subtype and endpoint definitions, it must be
considered that Broukhaert et al. used tumor grade
instead of Ki-67 for defining subtypes, (with the associated
problems mentioned above), and Minicozzi et al. studied a
retrospective cohort (2003–2005) with a different Ki-67
cut-off and lack of reliable information about how Ki-67
was determined at that time.
In our cohort the median age of early breast cancer
patients was 57 years compared to 64 years in Germany.
Concerning surgical procedures mastectomy was per-
formed in 26.9 % of all patients, which is lower than in a
current published report from the SEER database with a
mastectomy rate of 34 % showing an increase in the
United States especially in women with node-negative
Fig. 1 LCR, ROS, OS, DDFS and DFS-whole invasive cohort. Kaplan-Meier survival plot for LCR, ROS, OS, DDFS, and DFS for the cohort of invasive
cases. Shown are annual survival rates. The table presents the effective sample size for each interval. [LCR: local recurrence rate; DFS: disease-free
survival; DDFS: distant disease-free survival; OS: observed overall survival; ROS: relative overall survival]
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and in-situ disease (Table 1) [38]. The widely use of
specific anti-HER2 therapy in this cohort could increase
outcome for patients with HER2 positive breast cancer
[39]. The subgroup of patients with Luminal B/HER2
positive-like reveals a LCR of 95.0 % (95 % CI 91.3; 98.7)
and a ROS of 93.4 % (95 % CI 91.2; 100.8) at 5 years.
Note, however, that the HER2-type subgroup had the
second poorest outcome with a LCR of 90.5 % (95 % CI
84.7; 96.3) and a ROS of 88.8 % (95 % CI 81.5; 96.1)
(Table 3). The poor survival of triple-negative tumors
reflects the lack of effective and specific therapy for this
subgroup of patients.
Strengths and limitations
This study adds recent up-to-date outcomes for the 5
different molecular subtypes from a large prospective
cohort with a broad usage of Ki-67 for subtype definition
(with a cut-off at 14 %). Unfortunately the subgroups in
this study are too small with a favorable outcome and
the analysis is underpowered to exhibit further differ-
ences in stage distribution as well as surgical and
systemic management of primary breast cancer on out-
come. The effective disentangling of these and further
possible effect would require far larger sample sizes than
are present in our data base, and should be pursued
within cooperative research projects [40].
In our study, the cohort mirrors the typical, unselected
cohort of breast cancer patients treated at a specialized
breast cancer unit, as there were no specific exclusion
criteria. Unfortunately, we did not systematically docu-
ment a performance status describing comorbidities. As
a prospective, single center study, we cannot exclude
any potential center effects that may have confounded
the results. Further outcome studies from other clinical
settings may help to identify if and to what extent out-
comes may vary between different breast units.
Conclusion
If primary BC is managed at a specialized BCU under
guideline-adherent conditions, patients with a favorable
subtype can expect an OS above 95 % and an LCR of
almost 100 % over 5 years. On the other hand the outcome
of patients with HER2 and TN subtypes remains poor, thus
necessitating more intensified research and care.
Additional files
Additional file 1: Table S4. Case frequency for subtypes along UICC
stages for patients treated at Heidelberg Breast Care Unit between 01
January 2003, and 31 December 2012). (DOCX 18 kb)
Additional file 2: Table S5. Patient characteristics along breast cancer
subtypes for patients diagnosed at Heidelberg Breast Care Unit between
01 January 2003 and 31 December 31 2012. (DOCX 17 kb)
Additional file 3: Table S6. Five-year Overall Survival exemplary for 3
Subtypes subdivided into UICC stages I and IIa for patients treated at
Heidelberg Breast Care Unit between 01 January 2003 and 31 December
2012. (DOCX 15 kb)
Fig. 2 Overall Survival for Subtypes. Kaplan-Meier survival plot for overall survival according to molecular subtype (of invasive cancer). The annual
survival rates for the following subtypes are shown: LumA, LumB/HER2 neg., LumB/HER2 pos., HER2, and Triple negative (TN). The table presents
the effective sample size for each interval
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